Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.
Major reasons for the slow uptake of outcomes-based risk-sharing agreements in the U.S. are regulatory issues, operational requirements, and deficits in information sharing, according to a literature review published in JMCP.
This JMCP article describes how the Biosimilars Collective Intelligence Consortium (BBCIC) has the ability to coordinate sophisticated post-approval surveillance of biologics and biosimilars by utilizing its distributed research network.
Digital therapeutics: What are they, and where do they fit into pharmacy and medical benefits? Learn more in this blog post from AMCP CEO Susan A. Cantrell, RPh, CAE.